The influence of chronic renal failure on drug metabolism and transport

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 553-556

  Dreisbach, A W ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMFEBUTAMONE; ANDROGRAPHOLIDE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 2C11; CYTOCHROME P450 2C19; CYTOCHROME P450 2D; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; CYTOKINE; DEBRISOQUINE; ERYTHROMYCIN; FEXOFENADINE; GLYCOPROTEIN P; ISONIAZID; LIDOCAINE; MEPHENYTOIN; MESSENGER RNA; MIDAZOLAM; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; PARATHYROID HORMONE; PROCAINAMIDE; PROPRANOLOL; UREMIC TOXIN; WARFARIN;

BREATH ANALYSIS; CHRONIC KIDNEY FAILURE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; GENETIC POLYMORPHISM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; SHORT SURVEY; UREMIA;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; KIDNEY FAILURE, CHRONIC; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PARATHYROID HORMONE; PHARMACEUTICAL PREPARATIONS; UREMIA;

EID: 70350233303     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.163     Document Type: Short Survey

References (31)

1. Sun, H., Frassetto, L. & Benet, L.Z. Efects of renal failure on drug transport and metabolism. Pharmacol. Ther. 109, 1-11 (2006).
2. Frassetto, L.A., Poon, S., Tsourounis, C., Valera, C. & Benet, L.Z. Efects of uptake and efux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 81, 828-832 (2007).
3. Dreisbach, A.W. & Lertora, J.J. The efect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metab. Toxicol. 4, 1065-1074 (2008).
4. Nolin, T.D., Naud, J., Leblond, F.A. & Pichette, V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83, 898-903 (2008).
5. Naud, J. et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J. Pharmacol. Exp. Ther. 320, 978-985 (2007).
6. Veau, C. et al. Efect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol. Dial. Transplant. 16, 1607-1614 (2001).
7. Leblond, F.A., Petrucci, M., Dubé, P., Bernier, G., Bonnardeaux, A. & Pichette, V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J. Am. Soc. Nephrol. 13, 1579-1585 (2002).
8. Naud, J., Michaud, J., Leblond, F.A., Lefrancois, S., Bonnardeaux, A. & Pichette, V. Efects of chronic renal failure on liver drug transporters. Drug Metab. Dispos. 36, 124-128 (2008).
9. Laouari, D., Yang, R., Veau, C., Blanke, I. & Friedlander, G. Two apical multidrug transporters, P-gp and MRP2, are diferently altered in chronic renal failure. Am. J. Physiol. Renal Physiol. 280, F636-F645 (2001).
10. Uchida, N. et al. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn. J. Pharmacol. 68, 431-439 (1995).
11. Leblond, F.A., Giroux, L., Villeneuve, J.P. & Pichette, V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab. Dispos. 28, 1317-1320 (2000).
12. Leblond, F., Guévin, C., Demers, C., Pellerin, I., Gascon-Barré, M. & Pichette, V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 12, 326-332 (2001).
13. Michaud, J. et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 17, 3041-3048 (2006).
14. Simard, E. et al. Downregulation of hepatic acetylation of drugs in chronic renal failure. J. Am. Soc. Nephrol. 19, 1352-1359 (2008).
15. Michaud, J. et al. Efect of hemodialysis on hepatic cytochrome P450 functional expression. J. Pharmacol. Sci. 108, 157-163 (2008).
16. Sun, H., Huang, Y., Frassetto, L. & Benet, L.Z. Efects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32, 1239-1246 (2004).
17. Nolin, T.D., Frye, R.F., Sadr, H., Le, P. & Himmelfarb, J. The pharmacokinetics of fexofenadine but not midazolam are altered in end-stage renal disease. Clin. Pharmacol. Ther. 83, S58 (2008).
18. De Martin, S., Orlando, R., Bertoli, M., Pegoraro, P. & Palatini, P. Diferential efect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clin. Pharmacol. Ther. 80, 597-606 (2006).
19. Dreisbach, A.W. et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin. Pharmacol. Ther. 73, 475-477 (2003).
20. Frye, R.F. et al. Efect of renal insufciency on CYP. Clin. Pharmacol. Ther. 59, 155 (1996).
21. Dowling, T.C. et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin. Pharmacol. Ther. 73, 427-434 (2003).
22. Nolin, T.D., Appiah, K., Kendrick, S.A., Le, P., McMonagle, E. & Himmelfarb, J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J. Am. Soc. Nephrol. 17, 2363-2367 (2006).
23. Vinik, H.R., Reves, J.G., Greenblatt, D.J., Abernethy, D.R. & Smith, L.R. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59, 390-394 (1983).
24. Gibson, T.P., Atkinson, A.J., Matusik, E., Nelson, L.D. & Briggs, W.A. Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int. 12, 422-429 (1977). (Pubitemid 8294732)
25. Kim, Y.G. et al. Decreased acetylation of isoniazid in chronic renal failure. Clin. Pharmacol. Ther. 54, 612-620 (1993).
26. Turpeinen, M. et al. Efect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br. J. Clin. Pharmacol. 64, 165-173 (2007).
27. Osborne, R., Joel, S., Grebenik, K., Trew, D. & Slevin, M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin. Pharmacol. Ther. 54, 158-167 (1993).
28. Bianchetti, G. et al. Pharmacokinetics and efects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin. Pharmacokinet. 1, 373-384 (1976).
29. Zhang, Y. et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin. Pharmacol. Ther. 85, 305-311 (2009).
30. Gilbert, G.N., Moellering, R.C., Elipoulos, G.M., Chambers, H.F. & Saag, M.S. The Sanford Guide to Antimicrobial Therapy 2009 39th edn. (Antimicrobial Therapy, Sperryville, VA, 2009).
31. Aronof, G.R. et al. Drug Prescribing in Renal Failure 5th edn. (American College of Physicians, Philadelphia, PA, 2007).